Biofil Chemicals

Why is Biofil Chemicals & Pharmaceuticals Ltd falling/rising?

As of 07-Aug, the stock price of Biofil Chemicals & Pharmaceuticals Ltd is at 32.25, reflecting a decline of 0.92%. The stock is underperforming its sector, trading below moving averages, and has seen decreased investor participation, indicating ongoing downward pressure.

As of 07-Aug, the stock price of Biofil Chemicals & Pharmaceuticals Ltd is falling, currently at 32.25, which reflects a decrease of 0.3 or 0.92%. The stock has underperformed its sector by 1.04% today and is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a decline in investor participation, with delivery volume dropping by 5.96% compared to the 5-day average. Over the past month, the stock has decreased by 3.90%, while its year-to-date performance shows a decline of 5.51%. This overall trend indicates that the stock is experiencing downward pressure, contributing to its current falling price.

Which are the latest news on Biofil Chemicals?

Should I buy, sell or hold Biofil Chemicals & Pharmaceuticals Ltd?

How big is Biofil Chemicals?

As of 10th June, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 60.00 Cr, with recent net sales of 28.40 Cr and a net profit of 2.78 Cr. Shareholder's funds are 18.78 Cr and total assets amount to 50.96 Cr.

As of 10th June, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 60.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 28.40 Cr and a Net Profit of 2.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 18.78 Cr and Total Assets of 50.96 Cr.

Who are in the management team of Biofil Chemicals?

The management team of Biofil Chemicals includes Ramesh Shah (Chairman & Managing Director), Romil Shah (Non Executive Director), Shaila Jain, Satish Beohar, Ashok Kumar Ramawat, and Gayatri Padiyar (all Independent Directors), Ketan Shah (Whole-time Director), and Shweta Verma (Company Secretary & Compliance Officer). This team offers a diverse range of expertise to the company.

The management team of Biofil Chemicals includes the following individuals:<BR><BR>1. Ramesh Shah - Chairman & Managing Director<BR>2. Romil Shah - Non Executive Director<BR>3. Shaila Jain - Independent Director<BR>4. Satish Beohar - Independent Director<BR>5. Ashok Kumar Ramawat - Independent Director<BR>6. Ketan Shah - Whole-time Director<BR>7. Shweta Verma - Company Secretary & Compliance Officer<BR>8. Gayatri Padiyar - Independent Director<BR><BR>This team brings a diverse range of expertise to the company. If you have any more questions about Biofil Chemicals or its operations, feel free to ask!

Who are the peers of the Biofil Chemicals?

Biofil Chemicals' peers include Vineet Laborator, Samrat Pharma, Sunil Healthcare, Kabra Drugs, and others. Management risk varies from below average to good, with growth ratings ranging from below average to excellent, while Kabra Drugs leads in 1-year returns at 86.81%, compared to Biofil Chemicals' -33.45%.

Peers: The peers of Biofil Chemicals are Vineet Laborator, Samrat Pharma, Sunil Healthcare, Asston Pharmaceu, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, Veerhealth Care, and Vasundhara Rasy.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vineet Laborator, Sunil Healthcare, Kabra Drugs, Vivo Bio Tech, and Veerhealth Care, while Average management risk is found at Samrat Pharma, Asston Pharmaceu, and Shelter Pharma. Good management risk is noted at Vasundhara Rasy. Below Average growth is seen at Vineet Laborator, Samrat Pharma, Biofil Chemicals, Vivo Bio Tech, and the rest, while Good growth is present at Sunil Healthcare and Shelter Pharma, and Excellent growth is noted at Kabra Drugs. Average growth is found at Asston Pharmaceu, Veerhealth Care, and the rest. Capital Structure ratings show Excellent at Samrat Pharma and Shelter Pharma, Good at Biofil Chemicals, Veerhealth Care, and Vasundhara Rasy, and Below Average at Vineet Laborator, Sunil Healthcare, Kabra Drugs, Asston Pharmaceu, and the rest.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Samrat Pharma has the lowest at -41.51%. Biofil Chemicals' 1-year return of -33.45% is better than Samrat Pharma's but worse than Kabra Drugs'. Additionally, the six-month returns are negative for Samrat Pharma, Asston Pharmaceu, Vivo Bio Tech, and Shelter Pharma.

What does Biofil Chemicals do?

Biofil Chemicals & Pharmaceuticals Ltd manufactures and trades pharmaceutical products, classified as a Micro Cap company with a market cap of INR 60 Cr. As of March 2026, it reported net sales of 8 Cr and a net profit of 0 Cr.

Overview:<BR>Biofil Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated as a Private Limited Company on January 4, 1985, and later converted into a Public Limited Company on May 7, 1992. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 8 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 60 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.01<BR>- Return on Equity: 12.89%<BR>- Price to Book: 2.78<BR><BR>Contact Details:<BR>Address: 11/12 Sector E Sanwer Road, Sanwer Road Industrial Area Indore Madhya Pradesh : 452015<BR>Tel: 91-731-2426700<BR>Email: bcplcompliance@gmail.com<BR>Website: http://www.biofilgroup.net

Are Biofil Chemicals & Pharmaceuticals Ltd latest results good or bad?

Biofil Chemicals & Pharmaceuticals Ltd's latest results are mixed but lean negative, with a significant quarter-on-quarter sales increase overshadowed by a 9.34% year-on-year decline and a sharp drop in operating margin, indicating ongoing operational challenges and instability.

Biofil Chemicals & Pharmaceuticals Ltd's latest results present a mixed picture, leaning towards the negative. While there was a significant quarter-on-quarter increase in net sales of 780.23% to ₹7.57 crores and a net profit rise of 162.50% to ₹0.21 crores, these figures are somewhat misleading due to the extreme volatility in the company's revenue. <BR><BR>On a year-on-year basis, net sales actually declined by 9.34%, highlighting ongoing demand challenges. Additionally, the operating margin fell sharply from 11.63% to 5.68%, indicating deteriorating profitability despite the revenue increase. The company has also shown a concerning trend of extreme revenue fluctuations over recent quarters, which raises questions about its operational stability.<BR><BR>Overall, while there are some positive indicators in the short term, the underlying operational issues and the year-on-year decline in sales suggest that the results are not fundamentally strong. The company continues to face significant challenges in achieving consistent performance and sustainable growth.

When is the next results date for Biofil Chemicals & Pharmaceuticals Ltd?

The next results date for Biofil Chemicals & Pharmaceuticals Ltd is 30 May 2026.

The next results date for Biofil Chemicals & Pharmaceuticals Ltd is scheduled for 30 May 2026.

How has been the historical performance of Biofil Chemicals?

Biofil Chemicals has experienced fluctuating financial performance, with net sales declining from 40.04 Cr in March 2024 to 33.40 Cr in March 2025, alongside decreased profitability and negative cash flow in the latest fiscal year. Total assets and liabilities increased, indicating a challenging financial environment.

Answer:<BR>The historical performance of Biofil Chemicals shows fluctuations in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Biofil Chemicals reported net sales of 33.40 Cr in March 2025, down from 40.04 Cr in March 2024, but an increase from 30.04 Cr in March 2023. The total operating income followed a similar trend, peaking at 40.04 Cr in March 2024 and showing a decrease to 33.40 Cr in March 2025. The company's total expenditure, excluding depreciation, was 32.55 Cr in March 2025, down from 39.22 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 1.16 Cr, slightly lower than 1.31 Cr in March 2024. Profit before tax decreased to 0.74 Cr in March 2025 from 0.87 Cr in March 2024, while profit after tax was 0.56 Cr in March 2025, compared to 0.71 Cr in March 2024. The company's total assets increased to 50.96 Cr in March 2025 from 47.08 Cr in March 2024, with total liabilities also rising to 50.96 Cr from 47.08 Cr. The cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the data indicates a challenging financial environment for Biofil Chemicals, with declining sales and profitability in the latest fiscal year.

Is Biofil Chemicals overvalued or undervalued?

As of November 11, 2024, Biofil Chemicals is considered overvalued with a PE ratio of 87.13 and an EV to EBIT ratio of 87.37, underperforming the market with a year-to-date return of -6.93% and a low ROE of 2.99%.

As of 11 November 2024, Biofil Chemicals has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued, with a PE ratio of 87.13, an EV to EBIT ratio of 87.37, and a Price to Book Value of 4.74. These ratios indicate a significant premium compared to its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, both of which are also in the expensive to very expensive range.<BR><BR>In comparison to the broader market, Biofil Chemicals has underperformed on a year-to-date basis, with a return of -6.93% against the Sensex's 5.66%. This trend, combined with its high valuation ratios and low ROE of 2.99%, suggests that the stock may not justify its current price level, reinforcing the conclusion that it is overvalued.

What is the technical trend for Biofil Chemicals?

As of May 5, 2025, Biofil Chemicals shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and bearish monthly MACD, alongside daily moving averages that are also mildly bearish.

As of 5 May 2025, the technical trend for Biofil Chemicals has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands show a bullish trend on the weekly chart but are mildly bearish on the monthly, further indicating a lack of strong momentum. Moving averages on the daily chart are mildly bearish, which aligns with the overall trend. The KST and Dow Theory both present a mildly bullish outlook on the weekly, but remain mildly bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

Who are the top shareholders of the Biofil Chemicals?

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited with 13.9%, Starline Equifin Private Limited at 7.51%, and individual investors holding 38.31%. There are no pledged promoter holdings or mutual fund investments, and only one Foreign Institutional Investor holds a minimal stake.

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited, which holds the highest promoter stake at 13.9%. The highest public shareholder is Starline Equifin Private Limited, with a holding of 7.51%. Additionally, individual investors collectively hold 38.31% of the company's shares. There are no pledged promoter holdings and no mutual funds currently invested in the company. Only one Foreign Institutional Investor (FII) holds a stake, but it is minimal at 0.0%.

Has Biofil Chemicals declared dividend?

No Dividend History Available